Journey Medical Corp (DERM) Price & Analysis

Compare

106 Followers

DERM Stock Chart & Stats

$7.83

-$0.02(-0.58%)

At close: Jan 08 4:00 PM EST

$7.83

-$0.02(-0.58%)

Day’s Range― - ―

52-Week Range$3.54 - $9.40

Previous CloseN/A

Volume25.59K

Average Volume (3M)213.28K

Market Cap

$212.47M

Enterprise Value$178.06M

Total Cash (Recent Filing)$20.29M

Total Debt (Recent Filing)$25.28M

Price to Earnings (P/E)―

Beta0.22

Next Earnings

Mar 19, 2026

EPS Estimate

-0.05

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.09

Shares Outstanding21,135,904

10 Day Avg. Volume231,889

30 Day Avg. Volume213,279

Financial Highlights & Ratios

PEG Ratio-0.02

Price to Book (P/B)3.98

Price to Sales (P/S)1.42

P/FCF Ratio-8.75

Enterprise Value/Market Cap0.84

Enterprise Value/Revenue3.16

Enterprise Value/Gross Profit4.68

Enterprise Value/Ebitda-149.88

Forecast

1Y Price Target

$14.00

Price Target Upside78.80% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering3

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical EfficacyEfficacy results showed Emrosi achieved significantly greater improvements compared with placebo and doxycycline in treating rosacea.

Market AccessPayer access for Emrosi has continued to broaden, reaching over 100M covered commercial lives.

Product UptakeThe strong uptake of Emrosi, both refills and new scripts, has been highlighted.

Bears Say

Journey Medical Corp News

Journey Medical price target raised to $16 from $10 at Alliance Global

Alliance Global raised the firm’s price target on Journey Medical (DERM) to $16 from $10 and keeps a...

16d ago

DERM

Journey Medical reports Q3 EPS (9c), consensus (4c)

Reports Q3 revenue $17.63M, consensus $18.85M. Claude Maraoui, Journey Medical’s (DERM) co-founder, president and CEO, said, “Our third...

16d ago

DERM

Fourteen new option listings on November 12th

New option listings for November 12th include Direxion Daily AMD Bear 1X Shares (AMDD), Beta Bionics Inc (BBNX),...

16d ago

MST

PRE

Journey Medical’s Earnings Call Highlights Growth and Challenges

Journey Medical Corporation (($DERM)) has held its Q3 earnings call. Read on for the main highlights of the...

15d ago

DERM

Buy Rating for Journey Medical Corp Driven by Emrosi’s Market Success and Growth Potential

Analyst Brandon Folkes from H.C. Wainwright reiterated a Buy rating on Journey Medical Corp and keeping the price...

16d ago

DERM

Journey Medical Corporation Reports Strong Q3 2025 Growth

Journey Medical Corporation ( ($DERM) ) has released its Q3 earnings. Here is a breakdown of the information...

16d ago

DERM

Journey Medical Corporation (DERM) Q3 Earnings Cheat Sheet

Journey Medical Corporation (DERM) is scheduled to report 3rd quarter earnings on 11/12/2025, after the market closes. Regarding...

19d ago

DERM

Journey Medical presented efficacy data from two studies on Emrosi

Journey Medical (DERM) Corporation presented efficacy data from a pooled analysis of the two Phase 3 multicenter, randomized,...

1M ago

DERM

Journey Medical Corp Amends Credit Agreement with SWK

An announcement from Journey Medical Corp ( ($DERM) ) is now available. On September 25, 2025, Journey Medical...

2M ago

DERM

Journey Medical Corp Enters New Sales Agreement

The latest announcement is out from Journey Medical Corp ( ($DERM) ). On August 28, 2025, Journey Medical...

3M ago

DERM

Journey Medical initiated with a Buy at H.C. Wainwright

H.C. Wainwright analyst Brandon Folkes initiated coverage of Journey Medical (DERM) with a Buy rating and $13 price...

3M ago

DERM

Journey Medical’s Earnings Call: EMROSI’s Impact and Challenges

Journey Medical Corporation (($DERM)) has held its Q2 earnings call. Read on for the main highlights of the...

4M ago

DERM

Journey Medical price target raised to $13 from $9 at Lake Street

Lake Street raised the firm’s price target on Journey Medical (DERM) to $13 from $9 and keeps a...

4M ago

DERM

Journey Medical Corporation’s Strong Start with Emrosi™

Journey Medical Corporation ( ($DERM) ) has released its Q2 earnings. Here is a breakdown of the information...

4M ago

DERM

DERM FAQ

What was Journey Medical Corp’s price range in the past 12 months?

Journey Medical Corp lowest stock price was $3.54 and its highest was $9.40 in the past 12 months.

What is Journey Medical Corp’s market cap?

Journey Medical Corp’s market cap is $212.47M.

When is Journey Medical Corp’s upcoming earnings report date?

Journey Medical Corp’s upcoming earnings report date is Mar 19, 2026 which is in 110 days.

How were Journey Medical Corp’s earnings last quarter?

Journey Medical Corp released its earnings results on Nov 12, 2025. The company reported -$0.09 earnings per share for the quarter, missing the consensus estimate of -$0.048 by -$0.042.

Is Journey Medical Corp overvalued?

According to Wall Street analysts Journey Medical Corp’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Journey Medical Corp pay dividends?

Journey Medical Corp does not currently pay dividends.

What is Journey Medical Corp’s EPS estimate?

Journey Medical Corp’s EPS estimate is -0.05.

How many shares outstanding does Journey Medical Corp have?

Journey Medical Corp has 21,135,904 shares outstanding.

What happened to Journey Medical Corp’s price movement after its last earnings report?

Journey Medical Corp reported an EPS of -$0.09 in its last earnings report, missing expectations of -$0.048. Following the earnings report the stock price went down -15.308%.

Which hedge fund is a major shareholder of Journey Medical Corp?

Currently, no hedge funds are holding shares in DERM

Journey Medical Corp Stock Smart Score

Neutral

Fundamentals

Return on Equity

-47.05%

Trailing 12-Months

Asset Growth

33.02%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Journey Medical Corp

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant acne; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; Ximino, an oral minocycline drug for the treatment of moderate to severe acne; and Exelderm cream and solution for topical use. It also sells doxycycline hyclate tablets, minocycline hydrocholoride capsules, and sulconazole nitrate cream and solution. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona.

Journey Medical Corp (DERM) Earnings & Revenues

Historic Earnings Reports

DERM Earnings Call

Q3 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call reflects a positive sentiment overall, driven by strong revenue growth and successful launch metrics for Amrozi. However, there are challenges such as declining legacy product revenues and reliance on co-pay assistance programs due to generic competition and slower formulary adoption, which are being addressed through strategic initiatives.View all DERM earnings summaries

DERM Stock 12 Month Forecast

Average Price Target

$14.00

▲(78.80% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","17":"$17","5.75":"$5.75","9.5":"$9.5","13.25":"$13.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":16,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$16.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$14.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":13,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$13.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,5.75,9.5,13.25,17],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.12,8.726153846153846,9.332307692307692,9.938461538461539,10.544615384615383,11.150769230769232,11.756923076923076,12.363076923076923,12.96923076923077,13.575384615384616,14.181538461538462,14.787692307692307,15.393846153846155,{"y":16,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.12,8.572307692307692,9.024615384615384,9.476923076923077,9.929230769230768,10.381538461538462,10.833846153846153,11.286153846153846,11.738461538461538,12.19076923076923,12.643076923076922,13.095384615384615,13.547692307692309,{"y":14,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.12,8.495384615384614,8.87076923076923,9.246153846153845,9.62153846153846,9.996923076923077,10.372307692307691,10.747692307692308,11.123076923076923,11.498461538461537,11.873846153846154,12.249230769230769,12.624615384615385,{"y":13,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":6.17,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.84,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.91,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.55,"date":1738368000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":5.63,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.97,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.88,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.81,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.97,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.99,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.12,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.25,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.12,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >